← Eichor
Condition: Tace Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Tace

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Efficacy and Safety of Neo-Adjuvant TACE and Atezolizumab Plus Bevacizumab Therapy for High-Risk R
Phase 2 · 4 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07239245Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment
NA · 1 location(s) · Shanghai Zhongshan Hospital · NCT06794073DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT06397235Prognosis Stratification for Advanced HCC Receiving TACE with PD-1/PD-L1 Inhibitors and Molecular Target Therapies
Phase N/A · 1 location(s) · Zhongda Hospital · NCT06607120HAIC Compared With TACE in Huge Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT06641713Lparomlimab and Tuvonralimab Injection in Combination With TACE and Lenvatinib in the Treatment of Second-Line Therapy f
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07099274DEBIRI Plus Chemotherapy vs. Chemotherapy Alone in Colorectal Cancer Liver Metastases
Phase 3 · 1 location(s) · Tehran University of Medical Sciences · NCT06555003DEB-TACE Prior to Liver Transplantation in the Treatment of HCC
Phase 4 · 1 location(s) · RenJi Hospital · NCT06353126Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05613478TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
NA · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06487663Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocell
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT05970666A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Ca
Phase 2/Phase 3 · 2 location(s) · Zhejiang Raygene Pharmaceuticals Co., Ltd · NCT06844357Deep Learning-Based Multidimensional Body Composition Mapping for Outcome Prediction in HCC Patients Undergoing TACE
Phase N/A · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT07235410Triple Therapy Sequential Radiotherapy in Unresectable HCC (TALENP003)
Phase N/A · 4 location(s) · Fujian Provincial Hospital · NCT06561399Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib M
NA · 1 location(s) · Bangladesh Medical University · NCT07408804Multiparametric MRI for Characterization of Hepatocellular Carcinoma
Phase N/A · 1 location(s) · University Hospital Muenster · NCT06999174Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Phase 3 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07186621Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · Yoon Jun Kim · NCT06911255Liver Embolization Approaches for Tumor Management
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT05714124TACE Using Idarubicin Versus Doxorubicin Chemoemulsion in Patients with Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Seoul National University Hospital · NCT06114082Construction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinom
Phase N/A · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07417800Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
Phase 3 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05985798Atezolizumab and Bevacizumab Plus TACE-HAIC for Unresectable Advanced HCC: a Phase 2 Clinical Trial
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05751343A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination Wi
Phase 2 · 2 location(s) · TaiRx, Inc. · NCT07521852Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Phase 1/Phase 2 · 1 location(s) · VA Office of Research and Development · NCT05842174TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
Phase 2 · 2 location(s) · The University of Hong Kong · NCT04988945Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study
Phase 2 · 1 location(s) · Eye & ENT Hospital of Fudan University · NCT07320508Apatinib Mesylate and Camrelizumab Combined With TACE as Neoadjuvant Therapy for Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Wei Zhang · NCT07154082The Comparison of TACE-Lenvatinib With TACE-Lenvatinib-ablation for Intermediate Recurrent Hepatocellular Carcinoma
NA · 1 location(s) · Sun Yat-sen University · NCT06609850Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma
Phase N/A · 1 location(s) · University of Belgrade · NCT07378709
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.